Skip to main
PEN
PEN logo

Penumbra (PEN) Stock Forecast & Price Target

Penumbra (PEN) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 50%
Buy 35%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Penumbra Inc. demonstrated strong growth in its Thrombectomy segment, achieving record procedure volumes in December and an impressive year-over-year sales increase of 16.9%, contributing to a total of $222.7 million. Concurrently, the company's non-GAAP operating margins improved significantly, with a 200 basis point increase year-over-year due to enhanced gross margins—up 170 basis points to 67.4%—and reduced R&D expenses. The overall financial performance, highlighted by continued market share gains and improved productivity, positions Penumbra favorably within the medical device industry.

Bears say

The financial outlook for Penumbra Inc is increasingly negative, with projections indicating a decline in revenue growth to less than 12%, primarily due to underwhelming contributions from new products and slower-than-expected profitability improvements. There are significant risks identified, including competition leading to market share loss, delayed product clearances, and potential disruptions from supply chain issues, which compound the already lowered revenue estimates for 2025 and 2026. Furthermore, the international market presents challenges, particularly in China, while only partially benefiting from the introduction of CAVT products in Europe.

Penumbra (PEN) has been analyzed by 20 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 35% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Penumbra (PEN) Forecast

Analysts have given Penumbra (PEN) a Buy based on their latest research and market trends.

According to 20 analysts, Penumbra (PEN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $285.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $285.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Penumbra (PEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.